Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

Exclusion Criteria

• •Inability to provide voluntary consent
• •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
• •Pregnant, trying to become pregnant or breastfeeding
• •Prior diagnosis of coronary artery disease (CAD) or heart disease.
• •Systemic fungal infection
• •History of past or active mycobacterial infection with any species (including Mycobacterium tuberculosis). Latent Mycobacterium tuberculosis infection as indicated by a positive (more than 15mm induration)Purified Protein Derivative \[PPD\] skin test. Subjects with a positive PPD skin test and documented completion of treatment for latent TB are eligible. Subjects with a positive PPD skin test and not treated or no documentation of completion of treatment are ineligible.
• •History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years)
• •Clinically significant abnormality on the chest x-ray (CXR) at screening. Chest x-rays performed within 3 months prior to start of study drug are acceptable.
• •Use of any investigational medication within 4 weeks prior to start of study drug or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer)
• •History of Human Immunodeficiency Virus (HIV) infection or Hepatitis C
• •Positive Hepatitis B Surface antigen at screening
• •Malignancy or history of malignancy (except for treated \[ie, cured\] basal-cell skin carcinomas \> 3 years prior to screening)
• •History of any demyelinating disorder such as multiple sclerosis.